Immunotherapy cocktail shows promise in tough pancreatic cancer
NCT ID NCT03767582
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 23 times
Summary
This early-phase study tested a combination of three immunotherapy drugs (nivolumab, BMS-813160, and GVAX) in 22 adults with locally advanced pancreatic cancer that could not be removed by surgery. All participants had already received chemotherapy and radiation. The main goals were to check safety and see if the treatment could increase cancer-fighting immune cells inside the tumors. The study was completed, but results are not yet reported here.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21231, United States
Conditions
Explore the condition pages connected to this study.